ReviewFrontiers in cellular neuroscience2026
Mesenchymal vs. induced pluripotent stem cells: potential for spiral ganglion neuron regeneration in auditory neuropathy.
Review in Frontiers in cellular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Auditory neuropathy is a distinct form of sensorineural hearing loss characterized by dysfunction or degeneration of primary auditory neurons, also known as spiral ganglion neurons (SGNs), which transmit acoustic information from the cochlea to the brain. Increasing evidence indicates that SGNs are particularly susceptible to degeneration induced by noise exposure, ototoxic agents, genetic mutations, or aging, often preceding the loss of cochlear mechanosensory hair cells, and thus represents a critical target for regenerative intervention for auditory neuropathy. Stem cell-based approaches have emerged as promising strategies to restore auditory nerve function. In particular, the generation of otic neuronal progenitors (ONPs) capable of replacing damaged SGNs offers a translationally relevant avenue for therapy. Among candidate sources, mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs) offer distinct biological and translational advantages. iPSCs provide robust pluripotency and developmental recapitulation capacity, enabling efficient differentiation toward otic neuronal lineages, whereas MSCs offer immunomodulatory properties and paracrine neurotrophic support with lower tumorigenic risk. This mini-review critically compares MSC and iPSC-derived ONPs in terms of differentiation efficiency, neuronal maturation, integration potential, immunogenicity, and scalability. We further discuss emerging complementary strategies, including ONP transplantation, glial cell reprogramming and extracellular vesicle-based therapies. Together, these approaches highlight converging regenerative paradigms aimed at restoring auditory neuron function in neuropathic hearing loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.